A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 7, 2011, Pages 1088-1092

  Inamoto, Yoshihiro ^a   Flowers, Mary E D ^a   Appelbaum, Frederick R ^a   Carpenter, Paul A ^a   Deeg, H Joachim ^a   Furlong, Terry ^a   Kiem, Hans Peter ^a   Mielcarek, Marco ^a   Nash, Richard A ^a   Storb, Rainer F ^a   Witherspoon, Robert P ^a   Storer, Barry E ^a   Martin, Paul J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic; Cyclosporine; Graft versus host disease; Hematopoietic cell transplantation; Immunosuppressants; Tacrolimus

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; TACROLIMUS; URSODEOXYCHOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CELL MOTILITY; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE REGISTRY; FEMALE; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MOBILIZED BLOOD CELL; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONRELAPSE MORTALITY; ORGAN DONOR; OVERALL SURVIVAL; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RECURRENT CANCER; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CALCINEURIN; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STANDARD OF CARE; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79958724985     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.01.017     Document Type: Article

References (20)

1. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
2. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998, 92:2303-2314.
3. Hiraoka A., Ohashi Y., Okamoto S., et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001, 28:181-185.
4. Horowitz M.M., Przepiorka D., Bartels P., et al. Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. Biol Blood Marrow Transplant 1999, 5:180-186.
5. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2010. Available at: http://www.cibmtr.org.
6. Gratwohl A., Baldomero H., Frauendorfer K., Rocha V., Apperley J., Niederwieser D. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant 2008, 41:687-705.
7. Leisenring W.M., Martin P.J., Petersdorf E.W., et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006, 108:749-755.
8. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
9. Mielcarek M., Storer B.E., Boeckh M., et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009, 113:2888-2894.
10. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
11. Cutler C., Giri S., Jeyapalan S., Paniagua D., Viswanathan A., Antin J.H. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001, 19:3685-3691.
12. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087.
13. Eapen M., Logan B.R., Confer D.L., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007, 13:1461-1468.
14. Friedrichs B., Tichelli A., Bacigalupo A., et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010, 11:331-338.
15. Wingard J.R., Nash R.A., Przepiorka D., et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant 1998, 4:157-163.
16. Przepiorka D., Nash R.A., Wingard J.R., et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant 1999, 5:94-97.
17. Yanada M., Emi N., Naoe T., et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplant 2004, 34:331-337.
18. Fried R.H., Murakami C.S., Fisher L.D., Willson R.A., Sullivan K.M., McDonald G.B. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992, 116:624-629.
19. Ruutu T., Eriksson B., Remes K., et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002, 100:1977-1983.
20. Martin P.J., McDonald G.B., Sanders J.E., et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004, 10:320-327.